二十二碳六烯酸可减轻1-甲基-4-苯基-1,2,3,6-四氢吡啶猴模型中左旋多巴诱导的异动症。
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
作者信息
Samadi Pershia, Grégoire Laurent, Rouillard Claude, Bédard Paul J, Di Paolo Thérèse, Lévesque Daniel
机构信息
Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada.
出版信息
Ann Neurol. 2006 Feb;59(2):282-8. doi: 10.1002/ana.20738.
OBJECTIVE
The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.
METHODS
We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy.
RESULTS
DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease.
INTERPRETATION
These results suggest that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients.
目的
本研究的目的是调查多不饱和脂肪酸（ω-3）二十二碳六烯酸（DHA）对帕金森病1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）处理的猴子左旋多巴诱发的异动症（LIDs）的影响。
方法
我们在两种范式中探究了DHA的作用。首先，一组MPTP猴子在引入DHA之前用左旋多巴预处理几个月。第二组MPTP猴子（初治）在左旋多巴治疗前暴露于DHA。
结果
在两种范式中给予DHA均能减少异动症，且不改变左旋多巴的抗帕金森病作用，这表明DHA可以在帕金森病的非人灵长类动物模型中降低异动症的严重程度或延缓其发展。
解读
这些结果表明，DHA可以在帕金森病的非人灵长类动物模型中降低异动症的严重程度或延缓其发展。DHA可能代表了一种改善帕金森病患者生活质量的新方法。
Zotero 插件